Anti-Mouse VEGFR-2 Antibody (DC101)
Based on 1 Customer Validation
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
For research use only. We do not sell to patients.
- Purity : 99%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
|
VEGFR2 |
In Vivo
Anti-Mouse VEGFR-2 Antibody (DC101) (10 mg/kg, i.p., on day 2, 5 and 8) significantly inhibits tumor growth without significant toxicity in female BALB/c mice bearing H22 tumors[2].
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg, i.g., once every three days, for 4 weeks) significantly inhibits tumor growth and increases immune cell infiltration in female C57BL/6 mice bearing B16-OVA tumors[3].
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg, i.p., three times every week, for 21 days) significantly inhibits wound induced tumors in transgenic mice expressing CER of HPV8[4].
Anti-Mouse VEGFR-2 Antibody (DC101) (0.8 mg/mouse, i.p., twice weekly, for 2-3 weeks) inhibits tumor growth and increases T cell infiltration in FVB mice and Neu-N mice bearing NT2.5 tumors[5].
Anti-Mouse VEGFR-2 Antibody (DC101) (100 or 400 μg, i.p., once every three days, for 21 days) significantly reduces angiogenesis and endothelial cell count in female C57BL/6 mice injected with bFGF and VEGF[6].
Anti-Mouse VEGFR-2 Antibody (DC101) (800 μg, i.p., once every three days) significantly inhibits the growth of various tumors[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×106 253J B-V cells injected male athymic BALB/c nude mice (8-12 weeks)[1]
-
Dosage:1 mg/dose, combined with Paclitaxel (HY-B0015) 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice weekly for 4 weeks
-
Result:Significantly prolonged the survival period of mice.
Significantly reduced tumor microvascular density.
Enhanced apoptosis of tumor cells and endothelial cells.
-
Animal Model:2×106 H22 cells injected female BALB/c mice (6-8 weeks, 20 g)[2]
-
Dosage:10 mg/kg, combined with CA4 NPs (45 mg/kg) and anti-PD-1 (100 μg/mouse)
-
Administration:Intraperitoneal injection (i.p.) on day 2, 5 and 8
-
Result:Increased the number of CD8+ T cells within the tumor.
Significantly improved vascular perfusion.
Reduced the level of IFN-γ and TNF-α.
Had good safety in vivo.
-
Animal Model:5×105 B16-OVA cells injected female C57BL/6 mice (6-8 weeks)[3]
-
Dosage:40 mg/kg
-
Administration:Oral gavage (i.g.), once every three days for 4 weeks
-
Result:Significantly inhibited tumor volume.
Increased infiltration of CD3+ and CD8+ T cells.
Increased infiltration of B cells (CD19+) and dendritic cells (CD11c+).
Enhanced the expression of IFN-γ, perforin, and granzyme B in CD8+ T cells.
Reduced vascular density and increased perivascular cell coverage.
Significantly increased the density of PNAd+HEV and promoted the formation of tertiary lymphoid structures (TLS).
Upregulated PD-L1 expression in tumor cells and CD45+ immune cells, as well as PD-1 expression in CD3+ T cells.
-
Animal Model:Transgenic mice expressing CER of HPV8[4]
-
Dosage:40 mg/kg
-
Administration:Intraperitoneal injection (i.p.), three times every week for 21 days
-
Result:Reduced Ki-67+ proliferating cells and CD31+ vascular density.
-
Animal Model:5×106 NT2.5 cells injected FVB mice and Neu-N mice[5]
-
Dosage:0.8 mg/mouse
-
Administration:Intraperitoneal injection (i.p.), twice weekly for 2-3 weeks
-
Result:Increased CD4+ and CD8+ T cell infiltration.
Significantly inhibited tumor volume.
Decreased angiogenesis and increased tumor cell apoptosis.
-
Animal Model:Female C57BL/6 injected with bFGF (500 ng) and VEGF (10 μg)[6]
-
Dosage:100 or 400 μg
-
Administration:Intraperitoneal injection (i.p.), once every three days for 21 days
-
Result:Significantly reduced angiogenesis and endothelial cell count in matrigel plug model.
-
Animal Model:2×106 Lewis lung cells or 1×105 B16 cells injected female C57BL/6 mice (5-6 weeks), 1×105 4T1 cells injected female BALB/c mice (5-6 weeks), 2×106 A431, SK-RC-29, BxPC-3 or GBM-18 cells injected female athymic nu/nu mice (5-6 weeks)[6]
-
Dosage:800 μg
-
Administration:Intraperitoneal injection (i.p.), once every three days
-
Result:Significantly inhibited tumor growth.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay, Research in vivo
Verified Bioactivity
-
Immobilized VEGFR-2/Flk-1/KDR Fc Chimera Protein, Mouse can bind Anti-Mouse VEGFR-2 Antibody (DC101). The EC50 for this effect is 177.8 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse VEGFR-2 Antibody (DC101)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Inoue K, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000 Jul;6(7):2635-43. [Content Brief]
[2]. Bao X, et al. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics. 2021 Apr 3;11(12):5955-5969. [Content Brief]
[3]. Wang Z, et al. DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib. Biochem Biophys Res Commun. 2023 Jun 18;661:10-20. [Content Brief]
[4]. Ding X, et al. Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8. Cancer Res. 2015 Jan 15;75(2):330-43. [Content Brief]
[5]. Manning EA, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007 Jul 1;13(13):3951-9. [Content Brief]
[6]. Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999 Oct 15;59(20):5209-18. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse VEGFR-2 Antibody (DC101) Related Classifications
HY-P990106 Related Classifications
Powered by Bioz